Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: A Turn Of The Biotech Page

This article was originally published in Scrip

Executive Summary

In the bad old days before antibiotics and antimicrobial agents, patients only had their immune systems with which to fight infections. An antibacterial antibody response might take over a week to elicit but when the temperature of a patient with a systemic infection finally started to normalize, they could have been said to have turned the page, even if they were not yet out of the woods. There were some signs last week that the biotech fever that started in the summer of 2015 might be breaking.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel